Verona Pharma plc Verona Pharma To Announce Interim Results For Nine Months Ended September 30, 2018 And Provide Clinical Dev...
30 October 2018 - 5:00PM
UK Regulatory
TIDMVRP
LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that it will report its audited
financial results for the nine months ended September 30, 2018 on
Tuesday, November 6, 2018.
Verona Pharma will host an investment community conference call at 8:00
a.m. Eastern Standard Time (2:00 p.m. Greenwich Mean Time) on Tuesday,
November 6, 2018 to discuss the nine months financial results and
provide a clinical development update.
Analysts and investors may participate in the conference call by
utilizing the conference ID: 8100157 and dialing the following numbers:
-- 800-289-0571 or 929-477-0324 for callers in the United States
-- 0800 358 6377 or 44 (0)330 336 9126 for callers in the United Kingdom
-- 0800 589 4609 or 49 (0)69 2222 25577 for calls in Germany
Those interested in listening to the conference call live via the
internet may do so by visiting the "Investors" page of Verona Pharma's
website at www.veronapharma.com and clicking on the "Events and
presentations" link.
A webcast replay of the conference call (audio) will be available for 30
days on the "Investors" page of Verona Pharma's website at
www.veronapharma.com.
About Verona Pharma plc and RPL554
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. Verona
Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual
inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a
bronchodilator and an anti-inflammatory agent in a single compound. In
previous clinical trials, RPL554 has been observed to result in
bronchodilator effects when used alone or as an add-on treatment to
other COPD bronchodilators. It has shown clinically meaningful and
statistically significant improvements in lung function when
administered in addition to frequently used short- and long-acting
bronchodilators, such as tiotropium (Spiriva(R)), compared with such
bronchodilators administered as a single agent. RPL554 improved FEV(1)
over four weeks in patients with moderate-to-severe COPD when compared
to placebo and improved COPD symptoms and Quality of Life in a Phase 2b
multicenter European study performed in 403 patients. In addition,
RPL554 has shown anti-inflammatory effects in a standard challenge study
with COPD-like inflammation in human subjects. RPL554 has been well
tolerated in these studies and has a favorable safety and tolerability
profile, having been administered to more than 730 subjects in 12
clinical trials. Verona Pharma is developing RPL554 for the treatment of
COPD, cystic fibrosis ("CF"), and potentially asthma.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283
4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20
and UK Broker) 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727
1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
ICR, Inc. (US Media and Investor enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
(END) Dow Jones Newswires
October 30, 2018 02:00 ET (06:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma News Articles